INVESTORS & MEDIA

TARRYTOWN, N.Y., Nov. 25, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Leonard S. Schleifer, M.D., Ph.D., President, and Chief Executive Officer of Regeneron, and George D. Yancopoulos, M.D., Ph. D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories, have been named "Management Team of The Year" by Scrip Intelligence at the 9th annual Scrip Awards.  The award was announced last week by Scrip, a leading pharmaceutical industry publication.

"We are honored to have received this prestigious award," said Dr. Schleifer.  "None of this would have been possible without the dedicated efforts of our entire team and we accept this award on behalf of all the employees of Regeneron."

"Len and I, along with the entire Regeneron organization, are committed to a shared vision of developing innovative new scientific and technological approaches that can deliver life-changing medicines to patients," said Dr. Yancopoulos. "The last few years have been a transformational time for Regeneron, and we hope to continue our efforts to bring important new therapies to patients in need."

Award winners were selected by a 15-member panel of leading pharmaceutical industry executives, consultants, and researchers.  More information about the panel is available at:  http://www.scripintelligence.com/awards/judges/.  In addition to the "Management Team of the Year" award, a Phase 2a asthma study of dupilumab, which is being developed by Regeneron and Sanofi, was named "Clinical Advance of the Year" by Scrip Intelligence at the Scrip Awards.  In 2012, Scrip honored Regeneron as its Biotech Company of the Year.

About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis.  For additional information about the company, please visit www.regeneron.com.

Regeneron Forward-Looking Statements
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned, including without limitation dupilumab; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates; ongoing regulatory obligations and oversight impacting Regeneron's research and clinical programs and business; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare, to be cancelled or terminated without any further product success; and risks associated with third party intellectual property and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2012 and its Form 10-Q for the quarterly period ended September 30, 2013.  The reader is cautioned not to rely on any forward-looking statements made by Regeneron.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron Contacts:

SOURCE Regeneron Pharmaceuticals, Inc.